Skip to main content
DARZALEX 100 mg/5mL injection, solution, concentrate by Janssen Biotech, Inc.
DARZALEX, 100 mg/5mL, injection, solution, concentrate Drug class: CD38-directed Cytolytic Antibody. Available on prescription only. Listed by Janssen Biotech, Inc..
Prescription only

DARZALEX

Daratumumab

Listed by Janssen Biotech, Inc.

Strength
100 mg/5mL
Form
Injection, Solution, Concentrate
Route
Intravenous
Class
CD38-directed Cytolytic Antibody

What it contains

  • Daratumumab 100 mg/5mL

FDA record

Dosage form Injection, Solution, Concentrate
Route Intravenous
Drug class CD38-directed Cytolytic Antibody
Approval route BLA — biologic licence
NDC code 57894-502
FDA application BLA761036
RxNorm concept 1721951
Package sizes listed 2
Marketed since November 2015

Other products containing Daratumumab

See all

Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.

Darzalex Faspro

daratumumab and hyaluronidase-fihj (human recombinant)

Strength
1800 mg/15mL, 30000 U/15mL
Form
Injection
Class
CD38-directed Cytolytic Antibody; Endog…
Rx only

Janssen Biotech, Inc.

Not stocked by us — reference only

Darzalex IV

Daratumumab

Strength
100 mg/5mL
Form
Injection, Solution, Concentrate
Class
CD38-directed Cytolytic Antibody
Rx only

Janssen Biotech, Inc.

Not stocked by us — reference only

Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.